http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A Safety and Feasibility of Laparoscopic Left Side Liver Resection
( Ju Ik Moon ),( In Seok Choi ),( Jung Seok Lee ),( Sang Eok Lee ),( Nak Song Sung,),( Si Min Park ),( Dae Sung Yoon ),( Won Jun Choi ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Laparoscopic liver resection has become an alternative method for managing various liver tumors in the worldwide. However, the safety of laparoscopic liver resection still remains controversial. The aim of this study was to evaluate feasibility and a safety of laparoscopic left side liver resection based on 60 cases of laparoscopic liver resections in a single center. Methods: Between Jan. 2005 and Sept. 2016, 60 patients underwent laparoscopic left side liver resections at Konyang University Hospital, Daejeon, Korea. The following characteristics and results were retrospectively evaluated through the medical records. Results: A total of 60 cases were included in this study. The mean age of patients was 61.3 ± 11.0 years. The operations were performed left hemihepatectomy (LH) (n = 33, 55.0%), left lateral sectionectomy (LLS) (n = 27, 45.0%). During the follow periods left hemihepatectomy and left lateral sectionectomy were performed for IHD Stone (n = 37), HCC (n = 9), metastasis (n = 5), cholangiocarcinoma (n = 5), biliary cystadenoma (n = 2), hemangioma (n = 1) and angiomyolipoma (n = 1). Operative time was 318.4 ± 118.9 min and 217.5 ± 85.8 min in LH and LLS. A tendency of gradually decreased transecting time was observed in the left hemihepatectomy (R2 = 0.295; p < 0.001). There was no conversion to open surgery and no mortality. Complications occurred in the 6 (10.0 %) patients during the follow periods. Conclusions: According to our results, laparoscopic left hemihepatectomy and left lateral sectionectomy are safe and feasible procedures. We believe that laparoscopic left side liver resection has become the standard method for managing various liver tumors and diseases.
Moon, Ju Ik,Kwon, Choon Hyuck David,Joh, Jae-Won,Jung, Gum O.,Choi, Gyu-Seong,Park, Jae Berm,Kim, Jong Man,Shin, Milljae,Kim, Sung-Joo,Lee, Suk-Koo Wiley Subscription Services, Inc., A Wiley Company 2010 Liver transplantation Vol.16 No.7
<P>The problem of graft size is one of the critical factors limiting the expansion of adult-to-adult living donor liver transplantation (LDLT). We compared the outcome of LDLT recipients who received grafts with a graft-to-recipient weight ratio (GRWR) < 0.8% or a GRWR ≥ 0.8%, and we analyzed the risk factors affecting graft survival after small-for-size grafts (SFSGs) were used. Between June 1997 and April 2008, 427 patients underwent LDLT with right lobe grafts at the Department of Surgery of Samsung Medical Center. Recipients were divided into 2 groups: group A with a GRWR < 0.8% (n = 35) and group B with a GRWR ≥ 0.8% (n = 392). We retrospectively evaluated the recipient factors, donor factors, and operative factors through the medical records. Small-for-size dysfunction (SFSD) occurred in 2 of 35 patients (5.7%) in group A and in 14 of 392 patients (3.6%) in group B (P = 0.368). Graft survival rates at 1, 3, and 5 years were not different between the 2 groups (87.8%, 83.4%, and 74.1% versus 90.7%, 84.5%, and 79.4%, P = 0.852). However, when we analyzed risk factors within group A, donor age and middle hepatic vein tributary drainage were significant risk factors for graft survival according to univariate analysis (P = 0.042 and P = 0.038, respectively). Donor age was the only significant risk factor for poor graft survival according to multivariate analysis. The graft survival rates of recipients without SFSD tended to be higher than those of recipients with SFSD (85.3% versus 50.0%, P = 0.074). The graft survival rates of recipients with grafts from donors < 44 years old were significantly higher than those of recipients with grafts from donors ≥ 44 years old (92.2% versus 53.6%, P = 0.005). In conclusion, an SFSG (GRWR < 0.8%) can be used safely in adult-to-adult right lobe LDLT when a recipient is receiving the graft from a donor younger than 44 years. Liver Transpl 16:864–869, 2010. © 2010 AASLD.</P>
B형간염과 연관된 간세포암종의 근치적 절제술 후 혈관내피성장인자 아형의 발현양성 및 예후와의 관계
문주익 ( Ju Ik Moon ),김종만 ( Jong Man Kim ),정금오 ( Gum Oh Jung ),천재민 ( Jae Min Chun ),최규성 ( Gyu Seong Choi ),박재범 ( Jae Berm Park ),권준혁 ( Choon Hyuck David Kwon ),김성주 ( Sung Joo Kim ),조재원 ( Jae Won Jo ) 대한간학회 2008 Clinical and Molecular Hepatology(대한간학회지) Vol.14 No.2
방광암 환자에서 방광내 BCG 점적술 시행 후 발생한 육아종성 간염 1 예
손주익(Ju Ik Son),정준표(Jun Pyo Chung),백승석(Seung Suk Paek),이정일(Jung Il Lee),김정환(Jung Hwan Kim),문병수(Byung Soo Moon),이관식(Kwan Sik Lee),이상인(Sang In Lee),문영명(Young Myoung Moon),박찬일(Chan Il Park),김혜령(Hae Ryoung 대한소화기학회 2002 대한소화기학회지 Vol.39 No.5
Granulomatous hepatitis is a rare but serious systemic complication of intravesical Bacillus Calmette- Guerin (BCG) therapy, which has been proved more effective than most chemotherapeutic agents in the treatment of superficial bladder tumors and carcinoma in situ. Recently, we experienced a 64 year-old male with granulomatous hepatitis which had occurred following an intravesical BCG immunotherapy for an adjuvant treatment of superficial bladder cancer. The patient took isoniazid (300 mg) due to fever that had developed soon after an intravesical BCG immunotherapy. When he presented with clinical features of hepatic failure and sepsis, it was difficult to differentiate granulomatous hepatitis from isoniazid- induced hepatotoxicity. The patient died 20 days after the intravesical BCG immunotherapy (2 days after liver biopsy). This case indicates that granulomatous hepatitis is a fatal complication of the intravesical BCG therapy. Thus, a close follow- up and prompt diagnostic effort with optimal treatment should be instituted. (Korean J Gastroenterol 2002 ; 39: 375-378)